AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36891761 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anaemia (lowest haemoglobin concentration < 11 g dl -1)
Number of subjects: 7940
Study 36891761 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypotension (SBP < 90 mmHg)
Number of subjects: 7940
Study 36891761 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of postoperative anaemia and hypotension
Number of subjects: 7940
Study 36891761 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anaemia and hypotension
Number of subjects: 7940
Study 36891891 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impression
Number of subjects: 24
Study 36891891 — intervention group
Group type: COMPARATOR
Intervention: Alginate impression
Number of subjects: 24
Study 36891906 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 117
Study 36891906 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic therapy
Number of subjects: 117
Study 36891909 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 31
Study 36891979 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycosylation group (elevated levels of CA19-9, CA125, or CEA)
Number of subjects: 322
Study 36891979 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9
Number of subjects: 322
Study 36891979 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 322
Study 36891979 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 322
Study 36891979 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR expression in high glycosylation pNENs
Number of subjects: 322
Study 36891979 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycosylation
Number of subjects: 322
Study 36891995 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher muscle mass assessed by creatinine excretion rate
Number of subjects: 741
Study 36891995 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher muscle strength assessed by hand grip strength
Number of subjects: 741
Study 36891995 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle mass assessed by BIA
Number of subjects: 741
Study 36891995 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine assessment using both 24-h urine samples and hand grip strength
Number of subjects: 741
Study 36892042 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive left heart catheterization with left ventricular end-diastolic pressure measurement (≥16 mm Hg) for confirmation of HFpEF.
Number of subjects: 404
Study 36892053 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery
Number of subjects: 215
Study 36892053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried frailty scale
Number of subjects: 215
Study 36892053 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength, assistance with walking, rising from a chair, climbing stairs, and falls scales
Number of subjects: 215
Study 36892074 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective sleep duration of 5 hours or shorter
Number of subjects: 5027
Study 36892074 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported short (≤4 hours) sleep duration on weekdays and weekends
Number of subjects: 5027
Study 36892074 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported long (>8 hours) sleep duration on weekdays and weekends
Number of subjects: 5027
Study 36892074 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective sleep duration
Number of subjects: 5027
Study 36892074 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration
Number of subjects: 5027
Study 36892190 — intervention group
Group type: EXPERIMENTAL
Intervention: MW031 (60 mg)
Number of subjects: 119
Study 36892190 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (60 mg)
Number of subjects: 119
Study 36892190 — intervention group
Group type: EXPERIMENTAL
Intervention: MW031
Number of subjects: 119
Study 36892190 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 119
Study 36892220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 123
Study 36892220 — intervention group
Group type: COMPARATOR
Intervention: Slow-release misoprostol vaginal insert
Number of subjects: 123
Study 36892506 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA-Fenofibrate group (fenofibrate at a daily dose of 200 mg in addition to UDCA)
Number of subjects: 117
Study 36892506 — intervention group
Group type: COMPARATOR
Intervention: UDCA-only group (standard dose of UDCA)
Number of subjects: 117
Study 36892545 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe (EndoVigilant)
Number of subjects: 769
Study 36892545 — intervention group
Group type: COMPARATOR
Intervention: Non-CADe
Number of subjects: 769
Study 36892565 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-AZA/VEN (Azacitidine/Venetoclax)
Number of subjects: 0
Study 36892565 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC-Score
Number of subjects: 0
Study 36892600 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer surgery classified as R1 or R2
Number of subjects: 0
Study 36892600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TNM stage
Number of subjects: 0
Study 36892600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lymph node ratio
Number of subjects: 0
Study 36892600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Charlson comorbidity index score
Number of subjects: 0
Study 36892600 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA IV classification
Number of subjects: 0
Study 36892600 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse scores on EORTC and EQ-5D questionnaires
Number of subjects: 0
Study 36892605 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health advisors (CHAs) with family history of cancer
Number of subjects: 375
Study 36892605 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health advisors (CHAs) with personal history of cancer
Number of subjects: 375
Study 36892677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin and paclitaxel administration
Number of subjects: 11
Study 36892677 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration (previously published data)
Number of subjects: 11
Study 36892676 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m²
Number of subjects: 50
Study 36892707 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH therapy escalation
Number of subjects: 26
Study 36892714 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-Y-3L
Number of subjects: 289
Study 36892714 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-Y-5L
Number of subjects: 289
Study 36892723 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of adjuvant radiotherapy in patients with pCR after NST
Number of subjects: 595
Study 36892723 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 595
Study 36892723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Worry Scale
Number of subjects: 595
Study 36892723 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease specific survival
Number of subjects: 595
Study 36892723 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 595
Study 36892745 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1205c plus osimertinib
Number of subjects: 13
Study 36892753 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 180 mg
Number of subjects: 243
Study 36892753 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 360 mg
Number of subjects: 243
Study 36892753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 36892753 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 243
Study 36892780 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach Plus Message
Number of subjects: 161
Study 36892780 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach Plus Phone
Number of subjects: 161
Study 36892780 — intervention group
Group type: COMPARATOR
Intervention: Reach Plus
Number of subjects: 161
Study 36892833 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib, ipilimumab, and nivolumab (RIN) at the RP2D of regorafenib dosed at 80 mg daily, ipilimumab 1 mg/kg every 6 weeks, and nivolumab 240 mg every 2 weeks.
Number of subjects: 39
Study 36892833 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib at 40 mg/d on cycle 1 and 80 mg/d on cycle 2 and beyond.
Number of subjects: 39
Study 36892833 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib, ipilimumab, and nivolumab (RIN) at the RP2D for patients without liver metastases.
Number of subjects: 39
Study 36892847 — intervention group
Group type: COMPARATOR
Intervention: Alisertib 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1)
Number of subjects: 91
Study 36892847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg with standard-dose fulvestrant (arm 2)
Number of subjects: 91
Study 36892847 — intervention group
Group type: COMPARATOR
Intervention: Alisertib (arm 1)
Number of subjects: 91
Study 36892847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib with fulvestrant (arm 2)
Number of subjects: 91
Study 36892884 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment (PAT)
Number of subjects: 85
Study 36892884 — intervention group
Group type: COMPARATOR
Intervention: Negative Affect Treatment (NAT)
Number of subjects: 85
Study 36892916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild self-stigma
Number of subjects: 0
Study 36892916 — intervention group
Group type: COMPARATOR
Intervention: Moderate to high self-stigma
Number of subjects: 0
Study 36892929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary exposure treatment
Number of subjects: 0
Study 36892940 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX intervention
Number of subjects: 24
Study 36892945 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP uptake among women with mild depression symptoms
Number of subjects: 499
Study 36892945 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP refill requests among women with mild depression symptoms
Number of subjects: 499
Study 36892945 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence among women with mild depression symptoms
Number of subjects: 499
Study 36893079 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gait training
Number of subjects: 45
Study 36893079 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training
Number of subjects: 45
Study 36893079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rated executive function (DEX)
Number of subjects: 45
Study 36893091 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery-climate motor skills intervention (n = 70)
Number of subjects: 120
Study 36893091 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 50)
Number of subjects: 120
Study 36893091 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery-climate motor skills intervention
Number of subjects: 120
Study 36893205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking training program plus education and usual care
Number of subjects: 114
Study 36893205 — intervention group
Group type: COMPARATOR
Intervention: Educational and usual care only
Number of subjects: 114
Study 36893207 — intervention group
Group type: EXPERIMENTAL
Intervention: Team'IT observational tool
Number of subjects: 23
Study 36893453 — intervention group
Group type: EXPERIMENTAL
Intervention: TPO-RA discontinuation
Number of subjects: 48
Study 36893453 — intervention group
Group type: EXPERIMENTAL
Intervention: TPO-RA rechallenge
Number of subjects: 48
Study 36893575 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable bra with compression
Number of subjects: 201
Study 36893575 — intervention group
Group type: COMPARATOR
Intervention: Soft bra
Number of subjects: 201
Study 36893777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (CRP) quartiles
Number of subjects: 31245
Study 36893777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDLC) quartiles
Number of subjects: 31245
Study 36893785 — intervention group
Group type: EXPERIMENTAL
Intervention: nvHAP prevention bundle (oral care, dysphagia screening and management, mobilisation, discontinuation of non-indicated proton-pump inhibitors, respiratory therapy)
Number of subjects: 361947
Study 36893784 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 50 mg/kg (cohort 1a)
Number of subjects: 288
Study 36893784 — intervention group
Group type: COMPARATOR
Intervention: Single dose of oral praziquantel 40 mg/kg (cohort 1b)
Number of subjects: 288
Study 36893784 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 50 mg/kg (cohort 2)
Number of subjects: 288
Study 36893784 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 50 mg/kg (cohort 3)
Number of subjects: 288
Study 36893784 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 60 mg/kg (cohort 4b)
Number of subjects: 288
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (14 studies, 5830 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions for higher risk individuals (9 studies, 1513 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions for unselected populations (6 studies, 3780 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (12 studies, 5253 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions for higher risk individuals (9 studies, 1473 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (5 studies, 1848 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (2 studies, 1668 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (3 studies, 325 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (3 studies, 946 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision improvement interventions (3 studies, 1489 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision improvement interventions (1 study, 597 participants)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (1 study)
Number of subjects: 8463
Study 36893804 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (1 study, 110 participants)
Number of subjects: 8463
Study 36893935 — intervention group
Group type: EXPERIMENTAL
Intervention: KE+CHO (573 mg KE/kg body mass plus 110 g glucose)
Number of subjects: 12
Study 36893935 — intervention group
Group type: COMPARATOR
Intervention: CHO (110 g glucose)
Number of subjects: 12
Study 36893935 — intervention group
Group type: EXPERIMENTAL
Intervention: KE+CHO
Number of subjects: 12
Study 36893935 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 12
Study 36893988 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent +Family-based group
Number of subjects: 240
Study 36893988 — intervention group
Group type: COMPARATOR
Intervention: Newsletter +Family-based group
Number of subjects: 240
Study 36894129 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% chance of survival presented as text-only
Number of subjects: 1052
Study 36894129 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% chance of survival presented in a static pictograph
Number of subjects: 1052
Study 36894129 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% chance of survival presented in an iterative pictograph
Number of subjects: 1052
Study 36894129 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% chance of survival presented as text-only
Number of subjects: 1052
Study 36894129 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% chance of survival presented in a static pictograph
Number of subjects: 1052
Study 36894129 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% chance of survival presented in an iterative pictograph
Number of subjects: 1052
Study 36894129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive beliefs about chance of survival
Number of subjects: 1052
Study 36894197 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day continuous peripheral nerve block with ropivacaine
Number of subjects: 144
Study 36894197 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 144
Study 36894200 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Ethics Committee (CEC) implementation
Number of subjects: 0
Study 36894200 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys and interviews
Number of subjects: 0
Study 36894201 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health (MH) intervention including education, support, analgesics, and menstrual products.
Number of subjects: 303
Study 36894238 — intervention group
Group type: EXPERIMENTAL
Intervention: Fava beans
Number of subjects: 0
Study 36894239 — intervention group
Group type: COMPARATOR
Intervention: Acellular carbohydrate sources (e.g., flour-based whole-grain products)
Number of subjects: 193
Study 36894239 — intervention group
Group type: COMPARATOR
Intervention: Cellular carbohydrate sources (minimally processed foods with intact cellular structures)
Number of subjects: 193
Study 36894239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-fat (LCHF) diet
Number of subjects: 193
Study 36894239 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (Acellular, Cellular, LCHF)
Number of subjects: 193
Study 36894248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BCC and Paternal BCC
Number of subjects: 92
Study 36894248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BCC
Number of subjects: 92
Study 36894248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BCC and Food Vouchers
Number of subjects: 92
Study 36894250 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH carotenoid intake (13.1 mg daily)
Number of subjects: 20
Study 36894250 — intervention group
Group type: EXPERIMENTAL
Intervention: MED carotenoid intake (13.1 mg daily)
Number of subjects: 20
Study 36894250 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW carotenoid intake (13.1 mg daily)
Number of subjects: 20
Study 36894250 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 20
Study 36894249 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy US-Style Diet (H-US)
Number of subjects: 63
Study 36894249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (Med)
Number of subjects: 63
Study 36894249 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian Diet (Veg)
Number of subjects: 63
Study 36894249 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 63
Study 36894565 — intervention group
Group type: EXPERIMENTAL
Intervention: Osc+ (slow-paced breathing with HRV biofeedback)
Number of subjects: 108
Study 36894565 — intervention group
Group type: COMPARATOR
Intervention: Osc- (personalized strategies with HRV biofeedback)
Number of subjects: 108
Study 36894565 — intervention group
Group type: EXPERIMENTAL
Intervention: Osc+
Number of subjects: 108
Study 36894565 — intervention group
Group type: COMPARATOR
Intervention: Osc-
Number of subjects: 108
Study 36894651 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site DNA-based molecular diagnosis (GeneXpert)
Number of subjects: 584
Study 36894651 — intervention group
Group type: COMPARATOR
Intervention: Same-day smear microscopy
Number of subjects: 584
Study 36894810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered indocyanine green (ICG)
Number of subjects: 50
Study 36894810 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods for data classification
Number of subjects: 50
Study 36894823 — intervention group
Group type: EXPERIMENTAL
Intervention: DFT/DATx15 extended depth of focus toric intraocular lens
Number of subjects: 35
Study 36894877 — intervention group
Group type: EXPERIMENTAL
Intervention: POC targeted coagulopathy management and intraoperative administration of 5% albumin
Number of subjects: 67
Study 36894877 — intervention group
Group type: COMPARATOR
Intervention: Control (non-POC)
Number of subjects: 67
Study 36894879 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 73
Study 36894887 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain group
Number of subjects: 59
Study 36894887 — intervention group
Group type: COMPARATOR
Intervention: Low pain group
Number of subjects: 59
Study 36894900 — intervention group
Group type: EXPERIMENTAL
Intervention: MTM intervention (N=46)
Number of subjects: 90
Study 36894916 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Derived Tumor Organoids (PDTO) derived from HNSCC
Number of subjects: 0
Study 36894916 — intervention group
Group type: EXPERIMENTAL
Intervention: PDTO co-cultured with autologous immune cells
Number of subjects: 0
Study 36894916 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic and genetic analyses of PDTO
Number of subjects: 0
Study 36894921 — intervention group
Group type: EXPERIMENTAL
Intervention: Glar/Exenatide
Number of subjects: 73
Study 36894921 — intervention group
Group type: COMPARATOR
Intervention: Glar
Number of subjects: 73
Study 36894921 — intervention group
Group type: COMPARATOR
Intervention: Glar/Lispro
Number of subjects: 73
Study 36894938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 5
Study 36894938 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 4.5 mg
Number of subjects: 5
Study 36894940 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised treatment package for first-episode depression
Number of subjects: 800